ArticleJournal of clinical lipidology
Hypolipidemia is associated with the severity of COVID-19.
Article in Journal of clinical lipidology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 204 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
204 citing papers in PubMed, 9 syntheses or guidelines pooled it, 380 citations in OpenAlex.
- Pediatric endocrinopathies related to COVID-19: an update.World journal of pediatrics : WJP · 2023Pooled it
- Why do men have worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2022Pooled it
- Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies.Diabetes & metabolism · 2021 · on this mapPooled it
- Lipid profile as an indicator of COVID-19 severity: A systematic review and meta-analysis.Clinical nutrition ESPEN · 2021Pooled it
- Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis.Virology journal · 2021Pooled it
- A systematic review and meta-analysis of regional risk factors for critical outcomes of COVID-19 during early phase of the pandemic.Scientific reports · 2021Pooled it
- Cholesterol and Triglyceride Concentrations, COVID-19 Severity, and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression.Frontiers in public health · 2021Pooled it
- COVID-19 and Cardiomyopathy: A Systematic Review.Frontiers in cardiovascular medicine · 2021Pooled it
- [HDL-cholesterol concentration and risk of SARS-CoV-2 infection in people over 75 years of age: a cohort with half a million participants from the Community of Madrid].Hipertension y riesgo vascularGuideline
- Effect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection.Journal of lipid research · 2024Trial
- PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection.Journal of the American College of Cardiology · 2023Trial
- Very low HDL cholesterol in infectious mononucleosis with hepatitis: a real-world evidence study.Atherosclerosis plus · 2026Article
- Serum Apelin-13 and Galectin-3 in COVID-19: Associations With Routine Biochemical Parameters and Diagnostic Performance in a Case-Control Study.Journal of clinical laboratory analysis · 2026Article
- A quantitative metabolic signature of host response during SARS-CoV-2 infection and recovery.iScience · 2026Article
- Combining label-free Raman spectroscopy and machine learning to identify early biomarkers of COVID-19 disease severity and mortality.Journal of biomedical optics · 2026Article
- Differences in concentration of neuron-specific enolase (NSE), neutrophil elastase (NE), and calcium-binding protein S100B in viral diseases: a pilot study focused on normoglycemic COVID-19 patients.Frontiers in molecular biosciences · 2026Article
- Dynamic regulatory mechanism of cholesterol 25-hydroxylase-mediated antiviral response in RNA virus infections.Frontiers in cellular and infection microbiology · 2026Review
- Assessment of biochemical and hematological profiles in outpatients with serological evidence of SARS-CoV-2 infection.Frontiers in medicine · 2026Article
- Serum lipidome remodeling in viral pneumonia: from pathophysiology to therapeutics.Frontiers in immunology · 2026Review
- Evaluation of glucose metabolism, endocrine, and renal functions following vaccination in post-COVID-19 individuals: a longitudinal retrospective single-center cohort study.BMC infectious diseases · 2025Article
144 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany patients with coronavirus disease 2019 (COVID-19) suffer multiple organ dysfunctions. However, whether patients develop dyslipidemia is unknown.
objectiveIn this study, we aimed to investigate the pathological alterations of low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), and total cholesterol (TC) in COVID-19 patients and their relationships with the disease severity.
methodsA retrospective study was performed to examine serum levels of LDL-c, HDL-c, and TC on 597 COVID-19 patients (mild: 394; severe, 171; critical: 32) who were hospitalized in our center between February 1 and March 3, 2020. Age- and gender-matched normal subjects (n = 50) who had routine laboratory lipid tests between October 1 and November 1, 2019 in our center were included as the control group.
resultsLDL-c and TC levels were significantly lower in COVID-19 patients as compared with normal subjects (P < .001). There were significant and gradual decreases in levels of LDL-c (median (IQR) in mg/dL, mild: 91 (76, 104); severe: 86 (69, 102); critical: 69 (48, 81); P < .02) and TC (mild: 173 (148, 203); severe: 167 (138, 197); critical: 125 (95, 162); P < .05) across all three groups. HDL-c levels only decreased significantly in critical cases as compared with levels in mild and severe cases. LDL-c and TC levels inversely correlated with C-reactive protein and interleukin-6, and positively correlated with the number of lymphocytes in patients.
conclusionsDevelopment of hypolipidemia begins in patients with mild symptoms. It progressively becomes worse in an association with the disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.